Indegene Posts 11.4% Revenue Growth in Q1 FY25

Indegene Limited, a leading digital-first commercialisation services company, released its financial results for the quarter ended June 30, 2024.

The company achieved a revenue of ₹6,765 million in Q1 FY25, marking an 11.4% growth compared to Q1 FY24. Additionally, Indegene reported a robust EBITDA growth of 14.5% in Q1 FY25 over the same period last year. The company also successfully became a zero-debt entity. The profit after tax for Q1 FY25 stood at ₹877 million, up from ₹684 million in Q1 FY24.

Commenting on the financial performance for the quarter, the Chairman and CEO of Indegene Limited, Manish Gupta, said, “In Q1FY25, we achieved revenue growth of 11.4% and robust EBITDA growth of 14.5% vs Q1FY24. We continue to see momentum and growth with our largest client and a few of our Top 20 clients, with increased activity and volume levels tracking the larger pipeline of impending new product launches. Based on our conversations with our top clients, we anticipate similar momentum across the industry. Further, compared to last year, our pipeline is healthier, and the quality of conversations with clients is much better, which gives us confidence about driving robust growth in the medium term.”

“Our Q1FY25 EBITDA margin of 19.6% and PAT margin of 13.0% is an improvement of 50 bps and 170 bps vs Q1FY24. Indegene is now a zero-debt company with repayment of loans, and we anticipate the financial leverage to drive stronger PAT growth going forward”, said Suhas Prabhu, CFO, Indegene Limited.

Suhas further added, “Also, we continue to strengthen our technology and automation initiatives, which we believe will have a positive impact on the margin in the future. Further, we anticipate that the EBITDA margin would have a similar trajectory as FY24 with a stronger H2 compared to H1.”

About Indegene Limited

Indegene Limited is a digital-first life sciences commercialisation company that assists biopharmaceutical, emerging biotech, and medical device companies in developing products, bringing them to market, and enhancing their impact throughout the product lifecycle in a more efficient, effective, and modern manner.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.